A dark grid of evaluation tiles with green and blue highlights, representing expert-graded medical information AI answers.

Pharma · · 8 min read

AI for medical affairs: how to test the answers HCPs now get first

Acumen Editorial · Updated November 20, 2026

The first answer an HCP gets about your product is increasingly not yours. IQVIA reported in March 2026 that 54% of HCPs already use generative AI to access scientific information, rising to 75% among those born in 1990 or later. In an October 2025 survey of more than 1,000 US physicians, OpenEvidence was the most widely used AI tool, at 45%. IQVIA's authors call the shift a move "from share of voice to share of algorithmic trust."

The tools keep getting closer to the prescribing decision. OpenEvidence has added Access Intelligence, a free suite that answers clinician questions on more than 2,500 patient support programs, including copay savings and prior authorization materials (Fierce Healthcare). On November 16, OpenAI expanded ChatGPT for Healthcare at HLTH with upgraded clinical search and more than 20 healthcare plugins (HIT Consultant).

Medical affairs has been slower to adopt AI than other functions, because regulation and accuracy demands are higher (Consilience Strategy, 2026). That caution is correct. But caution is not a test plan. Here is how we would build one.

Why does medical affairs need its own AI evaluation?

Because the failure that matters most is not a wrong fact. It is an answer that is accurate and still unbalanced.

A Mount Sinai study in The Lancet Digital Health tested 12 models on 33 physician-written cases. When drug advertisements appeared in the context, models chose the advertised drug 47.6% of the time, against 35% without them (News-Medical, November 11, 2026). Nothing in the answer was false. The recommendation had simply moved.

Medical information teams spend their careers preventing exactly that. A standard response document is balanced by design: it states the label, the evidence and its limits, and the safety data, in that order. General benchmarks don't score any of this. They check whether a model knows medicine, not whether it answers an unsolicited request the way a medical information team would sign off on.

Which AI answers should medical affairs test?

Two groups, and most teams only test one.

The first is your own: the medical information chatbot, the MSL insight assistant, the literature summarizer, the medical-legal review aid. Internal LLM platforms are now standard at the top 50 pharma companies (Consilience Strategy, 2026). The use cases are clear: medical information content, KOL insight generation, medical-legal review support and training (IQVIA; IntuitionLabs).

The second is the public tools HCPs already use: clinical search engines, general assistants and EHR-embedded tools. You don't control them. You can still measure what they say about your therapeutic area, find where they misstate the label or drop safety data, and decide what evidence and content to publish in response. IQVIA's point is that visibility in AI answers now depends on credible evidence, guideline inclusion and clear comparative positioning.

What should a medical information test set contain?

Real questions, written by people who answer them for a living. A useful set has five parts:

  • **Real request types.** De-identified patterns from your medical information inbox: dosing in special populations, off-label questions, drug interactions, missed doses, comparative questions and requests for unpublished data.
  • **Reference answers.** Written by medical information specialists to the same standard as an approved standard response document, with citations.
  • **Rubrics.** Item-level criteria an expert can score: label accuracy, scientific balance, safety content, citation accuracy, handling of off-label questions and appropriate referral.
  • **Hard cases.** Questions with conflicting evidence, subgroup results, recent label changes or no good answer. These are where models fail and where averages hide it.
  • **Promotional pressure tests.** The same question with and without promotional content in context, so you can see whether the answer moves.

The Pharmacy Times review of AI drug information tools in July 2026 shows why the hard cases matter. In one study cited there, OpenEvidence was 95% accurate on long-acting injectable antipsychotic dosing questions and ChatGPT 40%, with most errors on missed-dose scenarios. In another, every chatbot response scored statistically lower than pharmacists' answers. The authors' conclusion: human judgment is still needed.

Who should grade the outputs?

The people your reviewers already trust. A generalist annotator can check grammar. A generalist can't tell when a summary leans on a post hoc analysis, leaves out a boxed warning or reads like a detail aid.

GraderWhat they catchWhat they missBest use
Generalist annotatorsFormatting, tone, obvious errorsLabel nuance, balance, off-label riskLow-risk content checks
LLM-as-judgeConsistency at volumeIts own blind spots, subtle imbalanceScreening after expert calibration
Your own medical reviewersEverything, with full contextTime: they are needed on launchesFinal sign-off and rubric approval
External MSLs and medical information specialistsLabel accuracy, balance, safety, citationsYour unpublished internal dataBuilding and scoring test sets at volume

Most teams end up with a mix: external experts build and score the test set, an LLM judge screens at volume once its scores agree with the experts, and internal reviewers approve the rubrics and sign off on releases.

How do you keep it inside your SOPs?

Treat the test set like any other controlled medical document. Each item should carry the grader's credentials and therapeutic area, the source documents, the version of the label it was checked against, the review history and how disagreements were resolved. When the label changes, the affected items change with it.

That record is what lets a medical director, a compliance lead or an auditor follow a decision back to a qualified person. It also answers the question every medical-legal review committee will ask: who checked this, against what?

Checklist: before an AI tool answers an HCP

  • Is the test set built from real medical information request types?
  • Are reference answers written to approved standard response document standards?
  • Do rubrics score balance and safety content, not only accuracy?
  • Are hard cases and off-label questions over-represented?
  • Have you tested answers with and without promotional content in context?
  • Are graders MSLs or medical information specialists in the right therapeutic area?
  • Does each item record the grader, sources, label version and adjudication?
  • Have you scored the public AI tools HCPs use for your therapeutic area?
  • Is there a schedule to re-test after label changes and model updates?

How Acumen helps

We work only in healthcare, life sciences and pharma. Acumen supplies credential-checked MSLs, medical information specialists, medical writers and regulatory writers, matched by therapeutic area. They write reference answers to medical information requests, build rubrics, score model outputs and review regulatory drafts. Each item ships with an audit trail your medical reviewers can follow.

See medical affairs and regulatory data. For building a wider test set, read how to build a pharma AI benchmark.

Request a sample dataset Schedule a conversation

FAQ

How should medical affairs evaluate an AI tool?

Build a test set from real medical information request types, have MSLs and medical information specialists write reference answers and rubrics, and score each output for label accuracy, scientific balance, safety content and citations. Over-represent hard and off-label cases, record who graded each item, and re-test after label changes and model updates.

Why isn't a general medical benchmark enough for medical affairs?

General benchmarks test whether a model knows medicine. Medical affairs needs to know whether an answer is balanced, on-label, complete on safety and properly cited. A Mount Sinai study found drug ads in context raised models' choice of the advertised drug from 35% to 47.6%, without any answer being factually wrong.

Should we test public AI tools HCPs use, or only our own?

Both. IQVIA reports 54% of HCPs already use generative AI to access scientific information. You can't control public tools, but you can measure what they say about your therapeutic area, find misstatements and missing safety data, and decide what evidence and content to publish in response.

Who should grade medical information AI outputs?

MSLs and medical information specialists in the right therapeutic area, with your own medical reviewers approving rubrics and signing off on releases. Generalist annotators miss label nuance and imbalance. An LLM judge can screen at volume, but only after its scores have been checked against expert grades on the same items.

What is a promotional pressure test?

It is the same medical information question asked with and without promotional content in the model's context. If the recommendation shifts toward the promoted product, the tool is not scientifically balanced. The Mount Sinai study in The Lancet Digital Health used this design across 12 models and 33 physician-written cases.

How do we keep AI evaluation inside our SOPs?

Treat the test set as a controlled medical document. Each item records the grader's credentials and therapeutic area, source documents, the label version it was checked against, review history and how disagreements were resolved. Update affected items when the label changes, so any decision can be traced to a qualified reviewer.

From the Acumen archive. Explore expert data and Healthcare & Pharma.

← Back to Insights